MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Fundamental Analysis

Canada • Toronto Stock Exchange • TSX:MBX • CA59501P1045

0.215 CAD

-0.02 (-6.52%)

Last: Jan 30, 2026, 07:00 PM

Fundamental Rating

Taking everything into account, MBX scores 4 out of 10 in our fundamental rating. MBX was compared to 23 industry peers in the Biotechnology industry. The financial health of MBX is average, but there are quite some concerns on its profitability. MBX is not valued too expensively and it also shows a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MBX has reported negative net income.
MBX had a negative operating cash flow in the past year.
In multiple years MBX reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: MBX reported negative operating cash flow in multiple years.

1.2 Ratios

Looking at the Return On Assets, with a value of -6.00%, MBX belongs to the top of the industry, outperforming 86.96% of the companies in the same industry.
With an excellent Return On Equity value of -8.08%, MBX belongs to the best of the industry, outperforming 86.96% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-6%
ROE	-8.08%
ROIC	N/A

ROA(3y)1.04%

ROA(5y)3.95%

ROE(3y)1.4%

ROE(5y)5.76%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MBX has a better Gross Margin (53.02%) than 82.61% of its industry peers.
In the last couple of years the Gross Margin of MBX has grown nicely.
The Profit Margin and Operating Margin are not available for MBX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	53.02%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-3.11%

GM growth 5Y3.66%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MBX has more shares outstanding
MBX has more shares outstanding than it did 5 years ago.
MBX has a worse debt/assets ratio than last year.

2.2 Solvency

MBX has an Altman-Z score of 1.55. This is a bad value and indicates that MBX is not financially healthy and even has some risk of bankruptcy.
MBX's Altman-Z score of 1.55 is amongst the best of the industry. MBX outperforms 86.96% of its industry peers.
A Debt/Equity ratio of 0.24 indicates that MBX is not too dependend on debt financing.
MBX has a Debt to Equity ratio (0.24) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.24
Debt/FCF	N/A
Altman-Z	1.55

ROIC/WACCN/A

WACC7.67%

2.3 Liquidity

MBX has a Current Ratio of 8.48. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
MBX's Current ratio of 8.48 is amongst the best of the industry. MBX outperforms 91.30% of its industry peers.
MBX has a Quick Ratio of 5.17. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
MBX's Quick ratio of 5.17 is amongst the best of the industry. MBX outperforms 86.96% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	8.48
Quick Ratio	5.17

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MBX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -163.28%.
Looking at the last year, MBX shows a very negative growth in Revenue. The Revenue has decreased by -26.81% in the last year.
MBX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.05% yearly.

EPS 1Y (TTM)-163.28%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-440.62%

Revenue 1Y (TTM)-26.81%

Revenue growth 3Y-0.87%

Revenue growth 5Y12.05%

Sales Q2Q%-40.51%

3.2 Future

MBX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.75% yearly.
The Revenue is expected to grow by 29.96% on average over the next years. This is a very strong growth

EPS Next Y33.33%

EPS Next 2Y52.75%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year35.93%

Revenue Next 2Y29.96%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MBX. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 5.32 indicates a rather cheap valuation of MBX.
Based on the Price/Forward Earnings ratio, MBX is valued cheaply inside the industry as 95.65% of the companies are valued more expensively.
MBX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.57.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	5.32

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, MBX is valued cheaply inside the industry as 91.30% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	128.17

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as MBX's earnings are expected to grow with 52.75% in the coming years.